Navigation Links
High-Dose Chemo Fails Against Small Cell Lung Cancers
Date:4/9/2008

Tripled dose was ineffective and toxic, so strategy should be abandoned, study says

WEDNESDAY, April 9 (HealthDay News) -- High-intensity chemotherapy does not improve the survival rate of patients with small cell lung cancer (SCLC), a new Swiss study concludes.

Testing on 140 patients in a randomized trial showed no statistically significant differences in survival rate or tumor size between groups receiving either standard or high doses of chemo over a three-year period. The findings were published online April 8 in the Journal of the National Cancer Institute.

Researchers thought upping the amount of chemotherapy might help the patients live longer because laboratory data had suggested that higher doses kill SCLC cells resistant to standard doses.

"The approach explored in the present trial succeeded in raising the peak dose, total dose and dose intensity of (the chemotherapy drugs) by threefold but has clearly been ineffective and highly toxic," the authors wrote. "As a result, this strategy should be abandoned."

SCLC accounts for almost 13 percent of lung cancer cases in the United States. While many patients initially respond to chemotherapy, most suffer disease recurrence relatively quickly.

The study, lead by Dr. Serge Leyvraz of the University Hospital in Lausanne, Switzerland, compared high-dose and standard-dose chemotherapy using the drug agents: ifosfamide, carboplatin and etoposide (ICE).

The survival rates in the group were similar: 18 percent of the high-dose patients were alive after three years, 19 percent of standard-dose patients survived. Tumor shrinkage was also similar in the two groups: 78 percent among the high-dose recipients and 68 percent in the standard-dose arm.

More information

The National Cancer Institute has more about lung cancer.


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Page: 1 2

Related medicine news :

1. High-dose chemo and stem cell transplant shows little or no survival benefit for breast cancer
2. High-Dose Chemo Provides Little Benefit to Breast Cancer Patients
3. High-Dose Chemo Helps Beat Rare Brain Cancer
4. Chemotherapy may be culprit for fatigue in breast cancer survivors
5. Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
6. To evade chemotherapy, some cancer cells mimic stem cells
7. New chemotherapy regimen prolongs survival in difficult-to-treat childhood brainstem gliomas
8. PET scans can accurately detect a breast tumors response to chemotherapy
9. Chemotherapy with gemcitabine delays progression of operable pancreatic cancer
10. New Software Program Helps Breast Cancer Survivors and Patients Fight Chemofog
11. Medicare modernization act did not change chemotherapy as feared
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... British researchers report that an alternative to the traditional ... their experiments, the scientists found that clasping hands transferred ... the other than what is known as a fist ... as a cultural substitute for the firm gripping of ... issue of the American Journal of Infection Control ...
(Date:7/28/2014)... do not divide unless there is enough oxygen present ... other cell types circumvent this rule. Researchers at The ... overrides the cells, warning signals, enabling cancers to continue ... the process, the researchers found that lysosomes the ... decisions. They also uncovered new evidence that certain drugs ...
(Date:7/28/2014)... Michigan (PRWEB) July 28, 2014 The ... Drs. Harris, Birkhill, Wang, Songe and Associates, PC that ... and countless tomorrows to come. , The HBWS ... responsible for more than $2.5 million in donations. Through ... title sponsors for the Oakwood Women’s Healthcare Classic for ...
(Date:7/28/2014)... Lake City, Utah (PRWEB) July 28, 2014 ... protein powders and drinks, announced that it will be ... drink line of products this summer. The additional flavors ... with clean pure taste-free protein , Inspire Pomegranate Razz ... Vanilla - flavor of soft-serve vanilla cone , Bariatric ...
(Date:7/28/2014)... UT Southwestern Medical Center cancer researchers have found ... the activity of a mutated cancer gene common ... SML-8-73-1 (SML), interferes with the KRAS gene, or ... produces proteins called K-Ras that influence when cells ... cells dividing uncontrollably and turning cancerous. These ...
Breaking Medicine News(10 mins):Health News:'Fist Bump' May Beat Handshake for Cleanliness 2Health News:'Fist Bump' May Beat Handshake for Cleanliness 3Health News:Cell's recycling center implicated in division decisions 2Health News:Bariatric Eating Announces Three New Protein Shake Flavors 2Health News:UTSW cancer researchers identify irreversible inhibitor for KRAS gene mutation 2
... 2011. Researchers from the University of Maryland School of Medicine ... of exercise and computerized memory training to see if those ... The type of memory that will be examined is known ... and use it in a new way. Many ...
... (DECEMBER 12, 2011) Autism Speaks North America,s ... National Institutes of Health (NIH) in announcing the addition ... a data federation site for the National Database for ... will help create the largest multidisciplinary source of autism ...
... and lethal of all human brain tumors that originate ... followed by both radiation therapy and chemotherapy with temozolomide. ... temozolomide. A team of researchers led by Sameer Agnihotri, ... that the protein APNG can contribute to GBM resistance ...
... - Researchers from Boston University School of Medicine (BUSM) ... receptor (A2bAR) as a possible new therapeutic target against ... cholesterol. The findings, which appear on-line in Circulation ... is a metabolite produced naturally by cells at low ...
... New research from the laboratory of Dr. Elizabeth Leadbetter at ... of vaccines. Dr. Leadbetter,s lab has discovered new properties of ... for enhancing protection against a number of different infections. This ... of the journal Nature Immunology (Vol. 13, pp. ...
... by blocking the export of key control molecules from ... treatment for chronic lymphocytic leukemia (CLL) and other incurable ... at the Ohio State University Comprehensive Cancer Center ... Research Institute (OSUCCC James)., The agent, called KPT-SINE, ...
Cached Medicine News:Health News:Exercise/memory research for Parkinson's 2Health News:Exercise/memory research for Parkinson's 3Health News:Autism Speaks Autism Genetic Resource Exchange joins NIH National Database for Autism Research 2Health News:Autism Speaks Autism Genetic Resource Exchange joins NIH National Database for Autism Research 3Health News:Researchers identify agent responsible for protection against early stages of atherosclerosis 2Health News:Trudeau Institute announces latest discovery in vaccine development 2Health News:Trudeau Institute announces latest discovery in vaccine development 3Health News:Novel export-inhibitor shows promise for treating CLL 2
(Date:7/28/2014)... 2014  MiMedx Group, Inc. (NASDAQ: MDXG ), an ... and bioimplants processed from human amniotic membrane, announced today its ... Highlights include: , Revenue exceeds upper end ... $25.6 million , Quarter-over-quarter revenue grew ... increases 181% over Q2 2013 and 40% sequentially over Q1 ...
(Date:7/28/2014)... , July 28, 2014   Stone & ... of off-label marketing and fraud claims between the ... Solutions, Inc. ("VSI").  The settlement covers fraud in ... for endovenous laser ablation of varicose veins for ... firm with a history of representing whistleblowers in ...
(Date:7/28/2014)... , July 28, 2014 /PRNewswire-iReach/ -- June 28 th , ... which has developed the AMAS cancer test, is making its ... To date, the test, which is a serum-based in vitro ... emerging as a significant tool in the fight against cancer ... With an estimated 17 million cancer survivors in the ...
Breaking Medicine Technology:MiMedx Announces Record Second Quarter Results 2MiMedx Announces Record Second Quarter Results 3MiMedx Announces Record Second Quarter Results 4MiMedx Announces Record Second Quarter Results 5MiMedx Announces Record Second Quarter Results 6MiMedx Announces Record Second Quarter Results 7MiMedx Announces Record Second Quarter Results 8MiMedx Announces Record Second Quarter Results 9MiMedx Announces Record Second Quarter Results 10MiMedx Announces Record Second Quarter Results 11MiMedx Announces Record Second Quarter Results 12MiMedx Announces Record Second Quarter Results 13MiMedx Announces Record Second Quarter Results 14MiMedx Announces Record Second Quarter Results 15MiMedx Announces Record Second Quarter Results 16MiMedx Announces Record Second Quarter Results 17MiMedx Announces Record Second Quarter Results 18Stone & Magnanini LLP Announces $520,000 Department of Justice False Claims Act Settlement With Vascular Solutions, Inc. 2Stone & Magnanini LLP Announces $520,000 Department of Justice False Claims Act Settlement With Vascular Solutions, Inc. 3Oncolab, Inc. Exhibits Pioneering AMAS Cancer Test at AACC 2
... safety profile of BSI-201 in ... subjects with advanced solid tumors -, BRISBANE, Calif., ... developing novel cancer therapies,today announced that data supporting its lead ... of Clinical Oncology annual,meeting in Chicago., Findings will be ...
... SGP ), a leader in advancing the ... infection, announced today that data from,several clinical studies ... therapy, as well as boceprevir, the,company,s investigational oral ... annual Digestive Disease Week (DDW) meeting to be ...
Cached Medicine Technology:BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 3Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 4Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 5Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 6Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 7
The LIGACLIP ERCA Endoscopic Rotating Multiple Clip Applier is intended for use on tubular structures or vessels wherever a metal ligating clip is indicated. The tissue being ligated should be consis...
... The LIGACLIP 20/20 Multiple Clip Applier is ... medium clips. This automatic instrument is preloaded ... each firing by means of the unique ... Clip Applier is reloadable once with a ...
... places one staple each time the instrument handles ... and are then formed, thus holding the tissue ... sizes: wide (having a clip span of 13.0 ... span of 9.9 mm before closure). The skin ...
... The Autosuture MULTIFIRE PREMIUM skin ... time the instrument handle is ... the skin and is then ... together. There are different sizes ...
Medicine Products: